Molecular Partners (MOLN)

• Market cap: $177M
• 1 day: 1.28%
• 5 days: 19.1%
• 1 month: 27.76%
• 3 months: 29.16%
• 6 months: 12.06%
• Year to date: -2.67%
• 1 year: -21.39%
• 5 years: -75.88%
• 10 years: -75.88%
• Sector: Healthcare
• Industry: Biotechnology

About: Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.

Employees: 159